Effient (Daiichi Sankyo) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Effient 2017 U.S. Promotional Audit Report” report has been added to ResearchAndMarkets.com’s offering.

The 5 Key Questions Addressed

How many physicians were reached by Effient through reportable promotional activity in 2017 and how does this compare to its peer set in the Stroke Prevention market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does Daiichi Sankyo’s depth of coverage vary within key specialties (e.g., Cardiology, Interventional Cardiology, Internal Medicine, Cardiac Electrophysiology, and Family Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians? How often are physicians receiving paid meals for Effient throughout the year (e.g., monthly, quarterly, annually)? Who were the most frequent meal recipients and top paid speakers for Effient in 2017?

Data Sources & Methodology

The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals. Over 700 paid interactions across 500 physicians made on behalf of Effient were carefully examined to support the analysis.

For more information about this report visit https://www.researchandmarkets.com/research/5rf37z/effient_daiichi?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005442/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 07:09 AM/DISC: 09/24/2018 07:09 AM


Update hourly